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December 8, 2009:2337–410 years of experience with HCM, and countless patients who
ave taken antibiotics for that purpose.
It is obvious to us that following the most recent AHA
ecommendations and withholding antibiotics from patients with
CM will unavoidably have the effect of unnecessarily creating
everal new cases of infective endocarditis each year. We are at a
oss to understand how these AHA recommendations (2), which
e believe should be revised, are in the best interests of the HCM
atient population.
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e rely on guidelines. When large amounts of data exist, we rely
n expert summaries to distill the data and to make evidence-based
ecommendations. When data are more scarce, we rely on experts
o thoughtfully weigh the existing data along with their own
xperience, balancing risks and benefits, and make recommenda-
ions in the best interest of patient welfare.
It might be said too often, or might be said not often enough,
hat guidelines are . . . only guidelines. It remains imperative, espe-
ially when data are scarce, to understand the nature of guideline
ecommendations, including the presence or absence of data to
upport them. Ultimately, the savvy clinician should help his or her
atients individually weigh the relative risks and benefits of any
iagnostic test, or any therapeutic or prophylactic intervention.
his author thanks Drs. Maron and Lever for their discussion
egarding my paper (1) and for adding their voices to those of other
hysicians who, having cared for patients at risk of or suffering
rom endocarditis, raise concern about the new antibiotic prophy-
axis guidelines (2), ask whether they represent the best balance of
isk versus benefit, and ask whether these recommendations are the
ost likely means to adequately protect our patients (3–5).
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tent Overexpansion
nd Myocardial No-Reflow
arly revascularization of the infarct-related artery by primary
ercutaneous coronary intervention has become the mainstay of
herapy, especially in ST-segment elevation myocardial infarction.hen performed early in the course of acute myocardial infarction,
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December 8, 2009:2337–41t has been shown to decrease mortality (1). However, in a number
f patients undergoing primary percutaneous coronary interven-
ion, epicardial coronary artery reperfusion does not translate into
yocardial reperfusion, a phenomenon referred to as no-reflow.
o-reflow has important clinical ramifications because it is asso-
iated with a worse prognosis (2). Niccoli et al. (2) discuss several
nvestigated strategies for prevention and treatment of no-reflow,
ncluding management of distal embolization, reducing reperfu-
ion times, and use of drugs such as glycoprotein IIb/IIIa antag-
nists. In this context, it is also clinically important to elaborate on
he potential increased risk of no-reflow that is seen when
eploying oversized stents. This notion was tested in 90 patients
iagnosed with new ST-segment elevation (3). In this study,
atients were divided into either the stent overexpansion group
n  25 patients; stent-to-artery ratio 1.2) or the stent nonover-
xpansion group (n  65; stent-to-artery ratio 1.2). Notably,
o-reflow was increased in the overexpansion group when com-
ared with the nonoverexpansion group (32% vs. 11%, respectively,
 0.031), and heart failure was seen more often (28% vs. 14%,
espectively, p  0.036), although there was less target lesion
evascularization during follow-up in the overexpansion group (3).
hus, during coronary stenting, the risks of stent overexpansion
hould be weighed against the benefits to limit the potential for
arm. Insofar as primary percutaneous coronary intervention has
merged as the preferred therapeutic method in ST-segment
levation myocardial infarctions, physicians should retain a height-
ned awareness of all clinically-relevant mechanisms implicated in
he phenomenon of no-reflow, including overexpansion of coro-
ary stents.
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eply
e thank Drs. John R. and Roger Kapoor for their interest in
ur article (1) and for their comments on the role of coronary
tent overexpansion in no-reflow. Iatrogenic coronary micro-
ascular dysfunction (type D in the Camici-Crea classification)
2) has emerged as an important cause of microvascular dys-unction, especially in the setting of primary percutaneous
oronary interventions (PCIs) (2). Thrombus and plaque ma-
erial can mechanically plug microcirculation and further in-
rease vasoconstriction due to the release of potent vasocon-
trictors by platelets. Accurate planning of a primary PCI is of
aramount importance including pharmacological prevention
f distal embolization and vasoconstriction by administration of
lycoprotein IIb-IIIa inhibitors and vasodilators, as well as
echanical prevention of thrombus dislodgment by thrombus
spiration, which has been shown to substantially improve
icrovascular function and survival in patients treated by a
rimary PCI (3). Another technical point to consider, whenever
ossible, is direct stenting, which seems to improve the micro-
ascular function compared with stenting preceded by balloon
re-dilation (4). Furthermore, stent overexpansion as well as
ggressive post-dilation should be avoided in this setting
ecause of the higher risk of no-reflow, as shown by Maekawa
t al. (5), probably due to the higher risk of distal embolization
rom unstable plaques compared with stable plaques (6). Fi-
ally, recent reports on the safety of the drug-eluting stent in
he setting of a primary PCI (7) suggest its possible use in the
ttempt to reduce target lesion revascularization, as is the case
n stable patients.
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